Dr. Jibran Ahmed
Claim this profileNational Institutes of Health Clinical Center
Studies Cancer
Studies Adenocarcinoma
5 reported clinical trials
9 drugs studied
Area of expertise
1Cancer
Stage IV
KRAS positive
BRAF positive
2Adenocarcinoma
Stage IV
HER2 positive
Stage III
Affiliated Hospitals
Clinical Trials Jibran Ahmed is currently running
Atezolizumab + Tiragolumab
for Rare Cancers
This trial tests if the combination of atezolizumab and tiragolumab can help treat patients with advanced rare solid tumors. Atezolizumab is a type of drug that helps the immune system fight cancer. These drugs aim to boost the immune system to fight cancer more effectively. The study will also collect samples to understand how the treatment works and who might benefit most from it.
Recruiting1 award Phase 2
Palbociclib + Binimetinib
for Pancreatic Cancer
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Recruiting1 award Phase 210 criteria
More about Jibran Ahmed
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jibran Ahmed has experience with
- Binimetinib
- Fluorouracil
- Oxaliplatin
- Ceralasertib
- Trastuzumab Deruxtecan
- Emavusertib (CA-4948)
Breakdown of trials Jibran Ahmed has run
Cancer
Adenocarcinoma
Solid Tumors
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jibran Ahmed specialize in?
Jibran Ahmed focuses on Cancer and Adenocarcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are KRAS positive.
Is Jibran Ahmed currently recruiting for clinical trials?
Yes, Jibran Ahmed is currently recruiting for 4 clinical trials in Bethesda Maryland. If you're interested in participating, you should apply.
Are there any treatments that Jibran Ahmed has studied deeply?
Yes, Jibran Ahmed has studied treatments such as Binimetinib, Fluorouracil, Oxaliplatin.
What is the best way to schedule an appointment with Jibran Ahmed?
Apply for one of the trials that Jibran Ahmed is conducting.
What is the office address of Jibran Ahmed?
The office of Jibran Ahmed is located at: National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States. This is the address for their practice at the National Institutes of Health Clinical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.